|17th November 2020||David J Matlin||441||Grant/award etc.||$0.00|
|28th October 2020||David J Matlin||4,587,647||Open or private sale||$32.70||$150,000,000.14|
|1st October 2020||Joseph Mannello||180,000||Grant/award etc.||$0.00|
|12th August 2020||David J Matlin||6,900,000||Open or private sale||$30.05||$207,345,000.00|
|20th July 2020||Robert J Hariri||15,300||Exercise of in-the-money or at-the-money derivatives securities (usually options)||$3.57||$54,621.00|
|31st March 2020||Joseph Mannello||16,529||Open or private purchase||$0.00|
|31st March 2020||Eric Zaltas||16,529||Grant/award etc.||$0.00|
|31st March 2020||Louis J. Aronne||29,752||Grant/award etc.||$0.00|
|31st March 2020||Christopher Pechock||45,455||Grant/award etc.||$0.00|
|31st March 2020||Christopher C Dewey||6,611||Open or private purchase||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
MYOS RENS Technology, Inc. engages in the discovery, development, and commercialization of advanced nutrition products, functional foods, and other technologies. Its primary product is Fortetropin, a proprietary bioactive composition derived from fertilized egg yolk.